Login to Your Account

Flexion Adds $20M in Series B on Newly Focused OA Pipeline

By Jennifer Boggs
Managing Editor

Monday, December 3, 2012
Flexion Therapeutics Inc. is proving that, in drug development, it pays to stay flexible. The company disclosed a $20 million Series B financing led by new investor Novo Ventures, joined by existing investors 5AM Ventures, Pfizer Venture Investments, Sofinnova Partners and Versant Ventures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription